Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era.

Lapão, Tânia; Barata, Rui; Jorge, Cristina; Flores, Carlos; Calado, Joaquim

http://hdl.handle.net/10400.17/5185

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
IJMSci.pdf		865.43 KB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

With the approval of tolvaptan as the first specific medicine for the treatment of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD), biomarker discovery has gained renewed interest as it is widely recognized that these will be crucial in clinical decision-making, serving as either prognostic or predictive tools. Since the marketing authorization was first issued in 2015 for ADPKD, tolvaptan has remained the sole pharmacological compound specifically targeting the disease. For ADPKD patients it is an invaluable medicine for retarding disease progression. Although the field of overall biomarker discovery and validation has been detailed in several publications, the role of inflammation remains largely overlooked in ADPKD. The current work aims to provide the reader with an updated review of inflammation biomarkers research in ADPKD, highlighting the role of urinary MCP-1 (monocyte chemoattractant protein-1) as the most promising tool.

Keywords

Animals Humans HSJ PAT CLIN HCC NEF Antidiuretic Hormone Receptor Antagonists* / therapeutic use Biomarkers* / urine Chemokine CCL2 / urine Inflammation* / metabolism Polycystic Kidney Autosomal Dominant* / metabolism Autosomal Dominant* / drug therapy Autosomal Dominant* / urine Tolvaptan* / therapeutic use